|
||||||
Cancer Cell Phospholipid Metabolism
Group Leader:
Members: Dr Mu Yao Research Fellow, Cancer Cell Phospholipid Metabolism Group, Level 3, Blackburn Building, USYD; Ph: 95155192; Fax: 95161273; myao@med.usyd.edu.au
Dr Paul Sved Cancer Cell Phospholipid Metabolism Group, Level 3, Blackburn Building, USYD; Ph: 0412003098; Fax: 95161273; psved@med.usyd.edu.au
Mr Soma Vignarajan PhD Candidate, Cancer Cell Phospholipid Metabolism, Level 3, Blackburn Building, USYD; Ph: 95155194; Fax: 95161273; svignar@med.usyd.edu.au
Mr Sheng Hua PhD Candidate, Cancer Cell Phospholipid Metabolism, Level 3, Blackburn Building, USYD; Ph: 95155191; Fax: 95161273; shua7254@mail.usyd.edu.au
Research Overview This research program aims to determine the effect of blocking phospholipase A2 enzyme on cancer progression. Our study is based on the knowledge that excessive intake of dietary arachidonic acid (AA) increases the risk for cancer development and progression, and over the past 50 years the dietary intake of AA has increased significantly in Western countries.
Our work focuses on investigating the mechanisms involved in the role of phosphospholipase A2, an enzyme necessary for AA release, in proliferation and cell cycle regulation in cancer. In addition, we are investigating the effect of blocking the enzyme in animal models of human cancer.
2008/2009 Highlights Discover a feed forward loop between cPLA2 and PI3K/Akt pathways in prostate cancer cells. Clinical Cancer Research 14(24):8070-9, 2008.
The discovery of the characteristic loss of Annexin and gain of PLA2 in prostate cancer has been included in the 2nd Edition of the Encyclopaedia of Cancer (2008).
The team has characterised a blue berry based phytochemicals for anti-cancer effect. A recent presentation of the work was selected by AACR for Newswothy session. A randomised clinical trial will begin in 2009.
The team has received invitation to contribute to the third volume of In Vitro Mutagenesis Protocols (2009) from Springer.
2008/2009 Publications 1.Patel M, Kurek C, and Dong Q. The arachidonic acid pathway and its role in prostate cancer development and progression. J Urol, 179(5):1668-75, 2008
2. Patel M, Singh J, Niknami M, Kurek C, Yao M, Lu S, Maclean F, King N, Gelb MH, Scott KF, Russell PM, Boulas J, Dong Q. Cytosolic Phospholipase A2- A Potential Therapeutic Target for Prostate Cancer. Clin Cancer Res, 14(24):8070-9, 2008
3. Niknami M, Patel M, Witting P, Dong Q. Aberrant activation of arachidonic acid and eicosanoid pathways - targets for treating prostate cancer. Recent patents in Endocrine, Metabolic & Immune Drug Discovery 2:9-15, 2008
4. Niknami M., Patel M., Witting P.K., and Dong Q. Molecules in Focus: Cytosolic Phospholipase A2-. Int. J. Biochem. Cell. Biol. 41(5):994-7.2008
5. Dong Q Phospholipase A2. In: The Cancer Encyclopedia, Ed. Manfred Schwab. Springer, UK 2008. ISBN: 978-3-540-47648-1, 2008
6. Assinder, S., Q Dong., Kovacevic, Z. and Richardson, D.R. The AKT, PTEN and TGF-β pathways: Establised and proposed biochemical integration in prostate cancer. Biochem. J. 2009 417(2):411-21, 2009
7. Assinder, S., Q Dong., Mangs, H, and Richardson, D.R. Pharmacological Targeting of the Integrated AKT, PTEN and TGF-&[beta] Pathways in Prostate Cancer." Mol Pharmacol. 75(3):429-36, 2009.
8. Salomon R, Young L, MacLeod D, Yu XL, and Dong Q. Probasin promoter driven expression of ID1 is not sufficient for carcinogenesis in rodent prostate. J Histochem Cytochem 57(6):599-604 2009.
9. M Yao¬, RA Taylor, MG Richards, P Sved, J Wong, D Eisinger, C Xie, R Salomon, GP Risbridger, and Q Dong. Prostate regenerating capacity of cultured human adult prostate epithelial cells. Cells Tissues Organs (in press)
10. Niknami M, Dong Q, Witting P. Pitfalls in the use of arachidonic acid oxidation products to assign lipoxygenase activity in cancer cells. Free Radical Research (in press) |
|
||||
